FDA Agrees Two Clearance Pathways for BioCardia's Helix Catheter, No Safety Concerns
BioCardia secured FDA agreement on two marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no concerns on safety, performance, or agent compatibility. FDA's preferred route ties Helix approval to CardiAMP cell therapy clearance or via a follow-on pre-submission for De Novo authorization.
1. FDA Pre-Submission Meeting Outcome
BioCardia met with the FDA in a pre-submission meeting, securing agreement on two marketing clearance pathways for the Helix Transendocardial Delivery Catheter and encountering no concerns on safety data, device performance, or agent compatibility.
2. Preferred Approval Routes for Helix
FDA stated its preferred approval route would be simultaneous clearance of Helix and the CardiAMP cell therapy system for heart failure, and suggested a follow-on pre-submission could enable Helix approval via the De Novo regulatory pathway.
3. Helix Catheter Features and Strategic Impact
The Helix catheter employs a small distal helical needle to deliver therapeutics intramyocardially with superior retention and access to multiple heart regions, and independent market clearance is expected to boost development and commercial partnerships for cell, gene, and protein therapeutics.